key: cord-0734162-dht2t8rd
authors: Lindahl, Ulf; Li, Jin‐Ping
title: Heparin – an old drug with multiple potential targets in Covid‐19 therapy
date: 2020-05-19
journal: J Thromb Haemost
DOI: 10.1111/jth.14898
sha: 8841995ac0d0844b476eb71114c8db26a151daa9
doc_id: 734162
cord_uid: dht2t8rd

A prominent clinical feature of severe Covid‐19 infection is respiratory failure associated with pulmonary coagulopathy. Recent reports published in Thrombosis and Haemostasis show that treatment with low‐molecular weight heparin (LMWH) decreases mortality in critically ill patients with sepsis‐induced hypercoagulation, and thus argue for prophylactic administration of the anticoagulant. In addition, the authors point to non‐anticoagulant activities of heparin, in particular anti‐inflammatory effects with potential to prevent deterioration of the disease. We would like to use this opportunity to clarify the biochemical background of the diverse activities of heparin, and further, how this information may be exploited to generate more efficient treatment of the viral infection. Mechanisms to consider relate to the functional roles of proteins interacting with heparan sulfate (HS), a polysaccharide closely related to heparin.

The highly sulfated glycosaminoglycan, heparin, has been used as an antithrombotic since the 1930'ies, and remains one of the most widely prescribed drugs today. The polysaccharide, a product of mast cells, is isolated from animal tissues (pig intestinal mucosa, bovine lung), and owes its anticoagulant activity to a specific pentasaccharide sequence (Fig. 1A ) that binds and activates antithrombin (AT), an inhibitor of proteases involved in blood coagulation. Only a fraction of the polysaccharide chains in heparin preparations contain the AT-binding pentasaccharide structure, hence bind AT with high affinity (HA-heparin) and show significant anticoagulant activity (5) . The low-affinity chains (LA-heparin) have low anticoagulant activity but otherwise polyanionic properties similar to those of HA-heparin. The partially depolymerized LMWH preferentially used in the clinic contains about 30% HA chains.

Contrary to heparin, HS is expressed by virtually all mammalian (and many nonmammalian) cells, in particular as cell-surface proteoglycans with HS chains exposed to the extracellular milieu. Heparin and HS contain the same saccharide building blocks. However, while heparin is largely composed of extended, heavily sulfated saccharide sequences, HS displays distinct domains, the sulfation patterns of which are regulated in cell-autonomous fashion (Fig.1A,B) . The negatively charged domains serve to bind a multitude of proteins, including growth factors and their receptors, cytokines, selectins, extracellular-matrix molecules, certain viral coat proteins and others. Some proteins bind selectively to cognate HS sequences, whereas others show less specificity (6) . Virtually all HS-binding proteins also interact with heparin, hence the term "heparin-binding proteins" (Fig. 1C) .

Following administration to patients heparin will not only activate AT, but may also affect the functional state of a variety of other proteins. By competing with cell-surface HS for protein binding, heparin will displace proteins from their HS-mediated anchoring and thus disrupt associated function. Effects of potential value in Covid-19 treatment include prevention of viral adhesion but also anti-inflammatory activity based on inhibition of neutrophil chemotaxis and leukocyte migration. The recurrent involvement of proteins bound to cell-surface HS is striking. Binding of a viral protein to cell-surface HS is often the first step in a cascade of interactions that is required for viral entry and the initiation of infection. Indeed, recent findings of heparin interacting with the receptor binding domain of the SARS-CoV-2 Spike S1 protein suggest potential to prevent viral adhesion (7) . Interactions of selectins and cytokines with HS expressed on endothelial cells control the recruitment of immune cells during inflammation (8) .

Notably, in a retrospective clinical study LMWH treatment of COVID-19 patients was found to significantly lower plasma levels of IL-6, a key player in the "cytokine storm" associated with severe outcome of the disease (9) . Potentially beneficial effects of heparin on initiation and progression of Covid-19 infection would thus be due to displacement of key protein protagonists from their HS scaffolds.

These considerations argue for increased attention to the non-anticoagulant properties of heparin in Covid-19 treatment, particularly so since the inflammatory phase is likely to precede the development of pulmonary microthrombi and impaired pulmonary gas exchange. However, due to the risk of bleeding complications the anticoagulant activity sets a limit to dosage of LMWH. In theory, this problem could be overcome by increasing the proportion of LA components, that are likely to harbor the protein-binding properties required. Unfortunately, pure LA-heparin is not available as a distinct drug. Instead, there are several reports of procedures to selectively eliminate the anticoagulant activity from heparin, without affecting the overall polyanionic properties (10) . We suggest that such products, that can be applied at higher dose, should be considered as a complement to conventional LMWH. Fig.1 Structural/functional relationship between heparin and heparan sulfate. (A) Conjectured heparin chain composed of alternating units of hexuronic acid (D-glucuronic acid, GlcA or L-iduronic acid, IdoA) and D-glucosamine (GlcN); sulfate groups are indicated by yellow circles. The ATbinding pentasaccharide sequence carries a unique sulfate group at carbon 3 of the internal GlcN residue; this 3-O-sulfate group is present in HA-but not in LA-heparin (5) . (B) HS structure, composed of the same building blocks as heparin, but with more sparse distribution of IdoA and sulfate residues. These components are typically accumulated in more densely sulfated domains that vary in structure depending on cellular origin. The sulfated domains provide sites for interactions of varying specificity with a multitude of proteins (6) . (C) Schematic illustration of two proteins with distinct requirements for binding structures on HS chains, yet both interacting with heparin. Rather than nonspecific, such interaction may depend on "hidden specificity", the selective HS epitopes being expressed also in the heavily sulfated heparin chain, albeit masked by redundant sulfate groups. 

Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia

The versatile heparin in COVID-19

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Evidence for a 3-O-sulfated Dglucosamine residue in the antithrombin-binding sequence of heparin

Interactions between heparan sulfate and proteins-design and functional implications

The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding

The Role of Heparan Sulfate in Inflammation, and the Development of Biomimetics as Anti-Inflammatory Strategies

The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study

Non-Anticoagulant Heparins as Heparanase Inhibitors